U.S. Sugar Demand Holds Despite Health Concerns, but GLP-1 Drugs Pose Long-Term Threat
Event summary
- U.S. sugar deliveries remain strong despite consumer intentions to reduce sugar intake.
- GLP-1 medications could cut U.S. food and beverage spending by $30 billion annually by 2030, per J.P. Morgan estimates.
- 75% of consumers in 2025 reported trying to limit or avoid sugar, but many reject artificial sweeteners as well.
- Stevia market growth is outpacing artificial sweeteners as consumers favor natural options.
The big picture
While current U.S. sugar demand remains resilient, long-term risks are emerging from health trends and GLP-1 medication use. The market faces a strategic anomaly where consumer intentions to reduce sugar intake haven't yet materialized in behavior, but structural shifts like patent expirations and dietary movements could reshape demand over the next decade.
What we're watching
- Health Trends Impact
- How GLP-1 medication adoption will affect sugar demand after 2031 when key patents expire.
- Consumer Preferences
- Whether natural sweeteners like stevia can sustain growth as consumers reject both sugar and artificial alternatives.
- Market Dynamics
- The pace at which health-focused initiatives translate into meaningful reductions in sugar consumption.